Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2010-N-0594]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
 DATES: Fax written comments on the collection of information by October 16, 2017.
 ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202-395-7285, or emailed to 
                        *oira_submission@omb.eop.gov.*
                         All comments should be identified with the OMB control number 0910-0497. Also include the FDA docket number found in brackets in the heading of this document.
 FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-8867, 
                        *PRAStaff@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Focus Groups as Used by the Food and Drug Administration (All FDA-Regulated Products), OMB Control Number 0910-0497. FDA conducts voluntary focus group interviews on a variety of topics involving FDA-regulated products, including drugs, biologics, devices, food, tobacco, and veterinary medicine. Focus groups provide an important role in gathering information because they allow for a more in-depth understanding of patients' and consumers' attitudes, beliefs, motivations, and feelings than do quantitative studies. Focus groups serve the narrowly defined need for direct and informal opinion on a specific topic and as a qualitative research tool have three major purposes: To obtain patient and consumer information that is useful for developing variables and measures for quantitative studies,
                To better understand patients' and consumers' attitudes and emotions in response to topics and concepts, and
                To further explore findings obtained from quantitative studies. FDA will use focus group findings to test and refine their ideas, but will generally conduct further research before making important decisions such as adopting new policies and allocating or redirecting significant resources to support these policies. In the 
                    **Federal Register**
                     of April 21, 2017 (82 FR 18763), FDA published a 60-day notice requesting public comment on the proposed collection of 
                    ( print page 43244)
                    information. No comments were received. FDA estimates the burden of this collection of information as follows: Table 1—Estimated Annual Reporting Burden 1
Activity
Number of
                             respondents
Annual
                             frequency 
                             per response
Total annual responses
Hours per
                             response
Total hoursFocus Group Interviews
8,800
1
8,800
1.75
15,4001
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 Dated: September 8, 2017. Leslie Kux, Associate Commissioner for Policy.


[FR Doc. 2017-19492 Filed 9-13-17; 8:45 am] BILLING CODE 4164-01-P